Neurosurgery Customer from Germany Orders Nexstim NBS System 5
Press release, Helsinki, 26 April 2024 at 3 PM (EEST)
Neurosurgery Customer from Germany Orders Nexstim NBS System 5
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery.
The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech function. The information gained from the mapping may be used in pre-procedural planning.
Mikko Karvinen, CEO of Nexstim, comments: “Our diagnostics system offers a unique possibility for neurosurgeons to receive crucial information about the location of vital functional areas before a surgery. We are happy to have one of our existing customers in Germany order a new NBS 5 system. This is a clear sign of the commitment that the Nexstim team has in maintaining long-term customer relationships in this important market, and of the real difference that our products are making in the everyday work of neurosurgeons and other medical professionals.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk A/S - share repurchase programme6.5.2024 20:44:48 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024 and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme6.5.2024 20:40:01 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.3% of the share capital and 77.4% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000 A shares of DKK 0.10 and 183,871,750 B shares of DKK 0.10, corresponding to 28.2% of the capital and 77.3% of the votes in Novo Nordisk A/S. The transaction is in line with th
Aktia Bank Abp: Anmälan om ändring av ägarandel i enlighet med kapitel 9 paragraf 10 i värdepappersmarknadslagen (Erkki Etolas ägarkontrollerade bolag)6.5.2024 19:30:00 CEST | Pressemelding
Aktia Bank Abp Börsmeddelande 6.5.2024 kl. 20.30 Aktia Bank Abp: Anmälan om ändring av ägarandel i enlighet med kapitel 9 paragraf 10 i värdepappersmarknadslagen (Erkki Etolas ägarkontrollerade bolag) Aktia Bank Abp har i enlighet med kapitel 9 paragraf 5 i värdepappersmarknadslagen emottagit anmälan av Erkki Etola, enligt vilken det av Erkki Etola kontrollerade bolaget Etola Group Oy:s innehav överskrider gränsen på 5 % av antalet aktier och röster i Aktia Bank Abp. De av Erkki Etola kontrollerade bolagens sammanlagda innehav av aktier och röster i Aktia Bank Abp överskrider inte flaggningsgränserna. Den information om aktieinnehav som presenteras i flaggningsmeddelandet återspeglar situationen efter de aktietransaktioner som genomfördes 6.5.2024. Det totala aktieinnehavet i Erkki Etolas kontrollerande bolag är oförändrat (9,75 %). Etola Group Oy:s aktieinnehav har redan överskridit gränsen på 5 % i och med aktieaffären 16.11.2023 och uppgick till 5,03 %. Detta överskridande har inte
Aktia Bank Plc: Disclosure under Chapter 9, Section 10 of the Finnish Securities Markets Act (Companies controlled by Erkki Etola)6.5.2024 19:30:00 CEST | Press release
Aktia Bank Plc Stock Exchange Release 6 May 2024 at 8.30 p.m. Aktia Bank Plc: Disclosure under Chapter 9, Section 10 of the Finnish Securities Markets Act (Companies controlled by Erkki Etola) Aktia Bank Plc has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Erkki Etola, according to which the holding of Etola Group Oy, the company controlled by Erkki Etola, exceeds the 5% threshold of the number of shares and voting rights in Aktia Bank Plc. The combined holdings of Erkki Etola's controlling companies of the number of shares and voting rights in Aktia Bank Plc do not exceed the flagging thresholds. The shareholding information presented in the disclosure statement reflects the situation after the share transactions executed on 6 May 2024. The total shareholding of Erkki Etola's controlling companies remains unchanged (9.75%). Etola Group Oy's shareholding has already exceeded the 5% threshold with the share transaction of 16
RevoluGROUP Canada Inc. Announces $1 Million Private Placement, Ex-CEO Marshall Outreach to Bernard Lonis Company Chairman6.5.2024 19:23:19 CEST | Press release
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces a non-brokered private placement of up to 20,000,000 units at a price of $0.05 each, to raise gross proceeds of up to $1,000,000. Each unit will consist of one common share and one warrant (each, a "Warrant") exercisable to purchase one additional common share at a price of $0.10 each for a period of one (1) year from the date of issuance. The expiry of the Warrants may be accelerated at the sole discretion of the Company by written notice if the closing price for the Common Share on the TSX Venture Exchange shall be equal to or greater than CAD $0.15 for a minimum of ten (10) consecutive trading days. Ex-CEO Steve Marshall could satisfy a sizable lead order for the Private Placement, pending the successful approval and completion of the subsequent commitments as specified below. The private placement is subject to TSX Ventur